Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$11.18
-1.3%
$9.24
$7.35
$14.65
$3.37B-0.02138,013 shs267,570 shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$24.54
-1.2%
$23.61
$14.75
$26.16
$2.99B0.71.10 million shs684,972 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.13
-0.2%
$25.80
$18.92
$81.73
$3.05B0.754.08 million shs2.51 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$11.23
+0.1%
$11.67
$8.21
$17.70
$780.65M1.24600,925 shs641,238 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
-1.32%+10.04%+37.85%-2.44%-20.09%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
-1.21%+0.90%+3.85%+13.30%+48.10%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.18%-0.44%+4.59%-5.37%-58.49%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+0.09%-5.95%-12.81%-15.82%+28.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alvotech stock logo
ALVO
Alvotech
2.3873 of 5 stars
3.54.00.00.02.70.00.6
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.873 of 5 stars
3.63.00.03.94.33.32.5
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.5747 of 5 stars
4.52.00.04.73.13.30.0
Zymeworks Inc. stock logo
ZYME
Zymeworks
3.1985 of 5 stars
4.50.00.00.02.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
3.00
Buy$18.0061.00% Upside
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.13
Buy$32.2931.56% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15221.25% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0087.00% Upside

Current Analyst Ratings Breakdown

Latest ZYME, ALVO, VKTX, and CPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$104.00
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $75.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/17/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/8/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$30.00
3/26/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/11/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$585.60M5.76N/AN/AN/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$534.65M5.60$2.29 per share10.72$3.30 per share7.44
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M8.37N/AN/A$6.63 per share1.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
-$551.73M$0.37N/A55.90N/A-123.47%N/A-35.87%N/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$71.41M$1.5720.8011.523.3131.01%40.79%34.87%8/6/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)

Latest ZYME, ALVO, VKTX, and CPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
5/7/2025Q1 2025
Alvotech stock logo
ALVO
Alvotech
-$0.17$0.35+$0.52$0.35N/AN/A
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
3/26/2025Q4 2024
Alvotech stock logo
ALVO
Alvotech
-$0.74-$0.24+$0.50-$0.24$97.99 million$153.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
2.69
1.92
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
5.11
4.92
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
0.46%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
4301.48 millionN/ANot Optionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80121.98 million106.15 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million106.20 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.58 million67.56 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVO

$11.18 -0.15 (-1.32%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$11.28 +0.10 (+0.90%)
As of 05/28/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$24.54 -0.30 (-1.21%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$24.68 +0.14 (+0.55%)
As of 05/28/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$27.13 -0.05 (-0.18%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$27.54 +0.41 (+1.49%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$11.23 +0.01 (+0.09%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$11.23 0.00 (0.00%)
As of 05/28/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.